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 Leigh syndrome is the most common mitochondrial disease, affecting 
1:40,000 live births. It manifests with symptoms including ataxia, cognitive 
impairment, motor difficulties, and stroke. Leigh syndrome is a genetic condition 
caused by mutations in either the nuclear DNA or mitochondrial DNA that affects 
the assembly of the electron transport chains. Death typically occurs around 2-3 
years of age, due to respiratory failure, as the body cannot produce sufficient ATP 
for survival. The genetic basis of Leigh syndrome means that there is no cure, and 
current treatments of the symptoms have proven ineffective. This thesis proposes 
two different therapeutic approaches for Leigh syndrome. The Ndufs4 knock-out 
(KO) mouse is an animal model of Leigh syndrome, and is the result of a mutation 
in complex I of the electron transport chain. This leads to symptoms almost 
identical to human patients including necrotizing lesions, seizures and motor 
impairments. The pathology in this model is associated with oxidative stress, 
protein succination, and inflammation. The therapeutic interventions selected are 
aimed at reducing these factors and the role that they play in disease progression.  
 N-acetylcysteine amide (NACA) is a precursor for glutathione, a powerful 
cellular antioxidant involved in the reduction of oxidative stress. In this study we 
administered NACA for 14 days and examined the effect on motor coordination in 
the mice. In addition, we examined the levels of a protein modification (protein 
vi 
succination) that is derived from the reaction of fumarate with protein thiols and is 
increased in the affected brain regions. We observed an improvement in the fine 
motor coordination in the mice receiving NACA for 14 days, highlighting the 
potential utility of this treatment; however, we did not detect reductions in oxidative 
stress markers or protein succination in association with this improvement. 
 Patients with Leigh syndrome display increased neuroinflammation and, in 
a similar manner, the Ndufs4 KO mouse also displays increased immune cells, 
particularly microglia, congregated in and around these lesions. PLX5622 is a 
microglial depletion drug and we hypothesized that decreasing the microglial 
content would decrease the inflammation, and contribute to improved survival and 
behavioral improvements. We also proposed that it may reduce protein succination 
in the brainstem as increased succination has recently been associated with 
macrophage activation. Overall, PLX5622 administration did not appear to be 
beneficial for the course of the pathology in the Ndufs4 KO mice, perhaps in part 
due to the severity of their symptoms and the need for some functional microglial 
presence to remove dying neurons.  
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1.1 Mitochondrial Respiration 
 Mitochondria are the “power-houses” of the cell, providing the body with 
~90% of cellular ATP via oxidative phosphorylation (OXPHOS) in all nucleated 
cells (1, 2). OXPHOS describes electron transfer through a series of 
oxidoreductase reactions known as the electron transport chain (ETC), coupled to 
the phosphorylation of ADP to ATP (Figure 1.1) (3, 4). The ETC consists of 5 
complexes that are embedded in the inner mitochondrial membrane, with electrons 
entering through complex I and/or II via NADH and/or FADH2, respectively. The 
electrons entering through complex I and/or II are transferred through the chain to 
reduce O2 to H2O at complex IV (3). Protons are simultaneously pumped at 
complexes I, III and IV from the matrix into the intermembrane space, creating an 
electrochemical gradient. Complex V (ATPase), also known as ATP synthase, 
uses the energy from protons re-entering the matrix, via the ATPase, to produce 
ATP from ADP and inorganic phosphate (3, 5).  
Mitochondria are also responsible for the production of reactive oxygen 




a basal level of ROS that can be involved in cell signaling, however, a disturbance 
in the ETC can cause an increase in the level of ROS produced, leading to 
oxidative stress (6). The reactive oxygen species hydrogen peroxide (H2O2) and 
superoxide are not necessarily toxic due to the presence of the antioxidant defense 
enzymes glutathione peroxidase and superoxide dismutase. However, when 
present in excess, they can react with metal ion catalysts and are further converted 
into hydroxyl radicals that react rapidly with intracellular proteins, lipids, and DNA, 
causing protein aggregation, lipid peroxidation, and DNA hydroxylation (7, 8). Free 
radical induced lipid peroxidation has been shown to also produce a variety of 
cytotoxic aldehydes, including 4-hydroxynonanal (HNE), whose adducts on 
proteins are commonly examined biomarkers of oxidative stress (7-9). Protein 
carbonylation refers to protein oxidation by ROS, with amino acid side chains 
forming reactive aldehydes, further reacting to cause aggregation and crosslinking 
(10). Intracellular stress caused by carbonylation may result in biomolecular 
malfunction and increased toxicity, leading to apoptotic cell death (11, 12). The 
accumulation of carbonylated proteins has been associated with affected brain 
regions of certain neurological disorders, particularly Alzheimer’s disease (12).  
1.2 Mitochondrial Respiratory Chain Disorders 
Mitochondrial respiratory chain disorders refer to conditions that are due to 
mutations in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) that 
impact the efficiency of OXPHOS, and occur in a wide range of encephalopathies 
and myopathies (13, 14). Mutations in the mtDNA can be the result of point 




individually, together these diseases occur with a prevalence of ~1:5000 (16). A 
mutual feature is a failure to thrive due to the lack of energy production in cells, 
specifically in organs that require more energy, such as muscle, brain, and the 
heart (17). Seizures are one of the most widely observed symptoms and occur in 
approximately 30-60% of the individuals with biochemically confirmed 
mitochondrial diseases (MDs), due to mitochondrial epilepsy (18-20). This is 
usually part of a larger, multi-system disorder, occurring in both early- and late-
onset MD (18, 21). 
 The well characterized MDs are Leber’s Hereditary Optic Neuropathy 
(Leber’s), Kearns-Sayre Syndrome (KSS), Mitochondrial Encephalomyopathy, 
Lactic Acidosis, and Stroke-like episodes (MELAS), Myoclonus Epilepsy with 
Ragged Red Fibers (MERRF), and Leigh Syndrome (LS). Leber’s, also known as 
LHON, is a maternally inherited mtDNA disease that can cause blindness (22). 
Leber’s is commonly due to primary or secondary mitochondrial dysfunction that 
affects retinal ganglion cell survival (23). Classically, symptoms begin suddenly 
around 15 to 35 years of age with the onset of central visual loss (24). The disease 
occurs predominantly in males, with loss of vision typically beginning in one eye 
and moving on to the second (bilateral) within a year (24, 25). There are three point 
mutations in mtDNA that are believed to lead to 90-95% of the cases of LHON 
known as ‘primary’ LHON mutations (26).  
 Kearns-Sayre Syndrome (KSS) is one of three phenotypes caused by 
single-deletions or duplications in mtDNA (27). As a multi-system disorder, KSS 




the retina, with ~50% of cases displaying cardiac involvement (28). Cardiac 
conduction blocks occur in varying degrees of severity, with polymorphic 
ventricular tachycardia being the most common (29).  
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) syndrome is one of the most common MDs. It is maternally inherited and 
has most commonly been attributed to a transition of adenine to guanine in 
nucleotide 3243 of mtDNA (2, 30, 31). MELAS patients show signs of dementia, 
muscle weakness, and epilepsy (2). The dementia is caused by both the cortical 
injuries and stroke-like episodes, resulting in neural difficulties including problems 
with language, perception, and memory function (2, 32).   
 Myoclonus epilepsy with ragged red fibers (MERRF) syndrome is an 
inherited MD with a prevalence of approximately 1:400,000 (33, 34). 80-90% of 
these cases are caused by an A8344G mutation in the mtDNA tRNALys gene (35-
37). Affecting mainly the nervous system and skeletal muscles, MERRF is known 
to cause myoclonus, muscular atrophy, epilepsy, and ataxia (38, 39). The defining 
characteristic of this disease is the ragged-red fibers in the muscles, containing 
subsarcolemmal aggregations of abnormal mitochondria; however, these muscle 
fibers have been seen in other MDs, such as KSS and Leigh Syndrome. Ragged-
red fibers are not typical of muscle and are seen as “myopathic”, with patients 






1.3 Leigh Syndrome 
The most common MD is Leigh Syndrome (LS), occurring in approximately 
1 in 40,000 live births (41). Linked to over 75 gene mutations, LS is a devastating 
neurodegenerative disorder (42, 43). LS was discovered by British 
neuropathologist Denis Leigh in 1951, when a 7 month old infant was admitted 
with encephalomyopathy and respiratory difficulties. Symptom onset began 
approximately six weeks prior to death and caused intense drowsiness, blindness, 
deafness, and spasticity of his limbs. During autopsy, the child’s brain showed 
lesions, vascular overgrowth, acute cellular swelling, and increased microglial 
presence (44). The onset of symptoms in LS normally occur in infancy, however, 
there have been cases of adult onset reported (45). Very few patients survive past 
the age of 10 years-old (43). Soufu et al. described a median onset age of 7 
months, with 80.8% of patients displaying symptoms by 2 years-old. Predictors of 
poor survival were seen as symptoms occurring at or under 6 months of age, failure 
to thrive, brainstem (BS) lesions, and requirement of intensive care (45). LS is now 
characterized by bilateral necrotizing lesions in the basal ganglia (BG), thalamus 
and BS, as well as respiratory failure, seizures, ataxia, cognitive impairment, and 
stroke (46). Biochemically, LS results in lactic acidosis, ensuing from the 
accumulation of pyruvate due to elevated levels of NADH. There have been 
reported increases in lactate and lactate:pyruvate ratios in blood, urine, and 
cerebrospinal fluid of patients (43). This increase in lactate has been displayed in 




Increased lactate in cerebrospinal fluid has been associated with a severe disease 
course (44).   
LS is most frequently the result of a mutation that leads to the impaired 
assembly of one of the five complexes of the ETC, but most commonly complexes 
I or IV (50). There have also been a number of cases reporting dysfunction in 
coenzyme Q or the pyruvate dehydrogenase complex as the cause of LS (43). 
Complex I is the largest complex of the OXPHOS system, with 45 different subunits 
folding together to create a large (980kD), L-shaped component (3, 51). This 
complex removes electrons from NADH to transfer them to ubiquinone, where they 
continue through the ETC. Approximately 30% of the defects in complex I are 
caused by a mutation in the mtDNA, most frequently MTND1, MTND3, and MTND5 
(52). Nuclear DNA mutations also contribute to LS. Assouline et al. described 
NADH:Ubiquinone oxidoreductase subunit S4 (NDUFS4) mutations that result in 
fatal, early-onset mitochondrial disease, specifically Leigh syndrome (53). Ndus4 
is a relatively small (18kD), nDNA-derived assembly protein that is believed to 
assist in the establishment of the tertiary structure of complex I, once Ndufs4 is 
phosphorylated (53-55). Loss of Ndufs4 causes complex I to form a smaller (~830 
kD) subcomplex that lacks NADH dehydrogenase (Figure 1.2) (56, 57). This is 
detrimental for optimal complex I activity, decreasing the amount of NADH that can 
be oxidized to NAD+. This subsequently reduces the levels of ATP generated by 
the ETC, as well as potentially increasing the number of ROS generated (57).  
The Ndufs4 knock-out (KO) mouse is used as an animal model of LS as it 




mouse was first described by Kruse et al. with a deletion of exon 2 causing a 
frameshift mutation halting the synthesis of the mature protein (58). The complete 
KO of complex I activity would most likely lead to embryonic death, yet the Ndufs4 
KO mouse survives for a limited lifespan, therefore the OXPHOS system must be 
able to compensate for this defect. Calvaruso et al. demonstrated that the Ndufs4 
KO mouse was able to survive due to the formation of a novel supercomplex. This 
supercomplex is formed between the partially assembled complex I and the fully 
functioning complex III, causing complex I to stabilize and allowing electrons to be 
transferred to ubiquinone (56). The phenotype of the KO mice was distinguishable 
from their wild-type (WT) littermates beginning at approximately postnatal day 21 
(p21), and the KOs die ~p50 (58). Quintana et al. verified that these mice 
experienced cognitive impairment, ataxia, respiratory distress, and defects in 
vision, all of which are symptoms of LS in humans (56). Light microscopy and 
electron microscopy have been used to visualize the pathological changes in brain 
regions that correspond to the deteriorating health of the mice, namely the BS and 
cerebellum (CB). The degree of gliosis and lesion development in these regions is 
similar to humans with LS. A significant difference in the mouse model and the 
human disease is that the basal ganglia (BG) appears to be unaffected in the KO 
mice (59).  
1.4 Mechanisms Contributing to the Pathology of Leigh Syndrome 
In addition to the reduced production of neuronal mitochondrial ATP, 
oxidative stress has been described to be increased in the fibroblasts of patients 




increased levels of H2O2, as well as superoxide anion radicals in the mitochondria. 
There was also evidence of increased protein carbonylation in these fibroblasts, 
indicating cumulative oxidative damage. These patients were further observed to 
have decreased antioxidant protection with lower levels of the enzymes catalase 
and superoxide dismutase 1 and 2 (61). Mitochondrial epilepsy has been linked to 
both ATP depletion in the brain, as well as oxidative stress. Epileptogenesis is 
characterized by neuronal hyperexcitability, which may be triggered by increased 
ROS production above what is required for synaptic signaling (62). 
Beyond the detection of lactic acidosis biochemically, the diagnosis of Leigh 
Syndrome is often performed via magnetic resonance imaging (MRI) which inicate 
bilaterally symmetric lesions, particularly in the BG, BS, and CB, before moving to 
genetic testing (63, 64). Microglia have been discovered to congregate at the 
periphery of these lesions, often in large numbers (44, 65). Microglia are the 
immune cells of the brain, comprising roughly 12% of cells, predominantly in the 
gray matter (66, 67). In a typical brain, these cells are at rest unless they are 
activated by events such as environmental stress or immunological challenges. 
Once activated, they undergo morphological and functional transformations to 
perform a diverse number of functions, such as phagocytosis of dying neurons and 
facilitating repair at the sight of inflammation and/or injury (67-69). However, in 
neurological disease, microglia can become over-activated and have been 
implicated in leading inflammation-mediated neuronal damage. These cells create 
a neurotoxic environment through the excess production of pro-inflammatory 




inflammation, particularly where the microglia are congregated around the lesions 
(44, 70). Quintana et al. demonstrated that complex I dysfunction in the Ndufs4 
KO is associated with the activation of glial cells, and further proposed that this 
leads to oxidative stress, cytokine release by microglia, and ultimately neuronal 
death via the extrinsic apoptotic pathway (59). 
S-(2-succino)cysteine (2SC) formation, also termed protein succination, 
refers to the reaction of fumarate with the thiol group on protein cysteine residues, 
generating an irreversible chemical modification (Figure 1.3) (71). Fumarate levels 
must be significantly heightened for this reaction to occur, and increased fumarate 
and protein succination has been described in adipocytes and obesity, as well as 
hereditary leiomyomatosis and renal cell cancer syndrome (72-76). Interesting, 
Barshop et al. reported increased fumarate and malate levels in the urine of 
patients with mitochondrial diseases (77), suggesting that elevated fumarate and 
protein succination may also have a role in the pathology of LS progression. As 
the ETC cannot function properly, NADH cannot be oxidized to NAD+, leading to 
an accrual of NADH and shortage of NAD+, inhibiting NAD+-dependent 
dehydrogenases and leading to the accumulation of fumarate and other Krebs 
cycle metabolites (14, 78). Piroli et al. demonstrated that protein succination is 
increased predominantly in the BS, olfactory bulbs (OB) and CB of the Ndufs4 KO 
mice (Figure 1.4). This was particularly increased in the vestibular nucleus (VN), a 
region of the brainstem that plays a significant role in motor coordination (Figure 




proteins modified (79, 80), suggesting that succination in the brain of the KO mice 
may also cause further damage to the already compromised mitochondria (14).  
Overall, in addition to the existing bioenergetics defect, the combined insults 
of oxidative, metabolite and inflammatory stress appear to be significant 
contributors to the progression of neuropathology in this model of LS. Despite this, 
the precise mechanisms linking the bioenergetics defect to neuronal cell death 
remain to be fully elucidated.  
1.5 Therapeutic Treatments for Leigh Syndrome 
There are over 75 different gene modifications that are responsible for LS, 
resulting in variable patterns of disease progression and symptom severity. Since 
there is no cure for this disease, physicians often face difficulty in generating an 
effective treatment plan. The typical treatment approach revolves around a cocktail 
of vitamins and supplements, such as coenzyme Q10 (CoQ10) and its derivatives 
(81, 82). CoQ10, or ubiquinone, is an electron carrier from complex I and II to 
complex III of the ETC (82, 83). In a patient with limited complex I activity, CoQ10 
may be administered in an attempt to bypass complex I via reducing equivalents 
entering the ETC through complex II and the oxidation of succinate, followed by 
transfer to complex III via CoQ10 (82, 84, 85). In its reduced form of ubiquinol, this 
directly acts as an antioxidant by preventing the initiation or propagation of lipid 
peroxidation (84). There are also indirect antioxidant properties of this coenzyme 
as it regenerates vitamins C and E, both of which may act as antioxidants (85). 




controversial results of CoQ10 as a treatment of mitochondrial disease (85-87). 
García-Corzo et al. demonstrated a water-soluble formulation of CoQ10 that 
reduced oxidative damage and increased body weight in Coq9x/x mice, but did not 
completely rescue the encephalopathic phenotype (85).   
In addition to CoQ10 treatments, riboflavin (B2) and folinic acid (B9) are 
frequently administered to LS patients. Riboflavin is believed to be useful in 
complex I deficiency due riboflavin being present in flavin mononucleotide (FMN). 
FMN is a prosthetic group of complex I, and has been documented as lacking in 
the muscle of patients with complex I deficiency (88, 89). Folinic acid is given to 
patients who suffer from central nervous system (CNS) manifestations (90). It is a 
reduced form of folic acid, and involved as a cofactor in many metabolic reactions 
(91).  
The common treatments for LS are not necessarily effective, nor do they 
provide a long term cure, therefore, new, alternative therapeutic practices are 
being studied. Rapamycin is an inhibitor of the mechanistic Target of Rapamycin 
(mTOR), and has been proven to increase lifespan in multiple models of different 
organisms (92-95). mTOR has functions in 2 complexes, mTORC1 and mTORC2, 
with rapamycin reacting with mTORC1. One of the main functions of mTORC1 is 
the promotion of mRNA translation and protein synthesis, with mTORC1 also 
helping to regulate autophagy. However, the activity of this pathway decreases as 
age increases. It is known that inhibition of mTORC1 increases autophagy, 
allowing the body to dispose of aged cells, therefore, its inhibition is believed to 




effects of rapamycin in Ndufs4 mice in order to distinguish if the longevity given by 
rapamycin would assist the KO mice past their normal maximum age of ~P50. 
Daily intraperitoneal injections were administered to the mice, allowing for an 
extension of life from ~P50 up to a maximum of P269. The treated mice did not 
display the signature lesions that age-matched, vehicle-treated mice did, nor did 
their behavior worsen as quickly with age. Unfortunately, this treatment does 
display some adverse effects, including immunosuppression, hyperlipidemia, and 
slow wound healing, all of which could prevent its use (96).  
Recently, Jain et al. used a Cas9-mediated knock-out screen to examine 
~18,000 genes in an effort to find a genetic factor for suppressing MD (81). Von 
Hippel-Lindau factor (VHL) was identified as the most effective factor in both 
severe and moderate diseases. VHL is a key factor in the regulation of the hypoxic 
pathway; a ubiquitin ligase that targets hypoxia-inducible transcription factors (HIF) 
for degredation. When VHL is knocked out, HIF is stabilized and the cells can 
bypass cellular oxygen sensing mechanisms. VHL-knock-out cells were found to 
be more resistant to complex I and complex V ETC dysfunction. To further 
translate this, Ndufs4 KO mice were treated with chronic moderate environmental 
hypoxia (11% O2), preventing development of many of the symptoms of LS, as 
well as extending life-span (81). This study was expanded upon and found that 
while their average normoxia-treated KO died ~P60, hypoxia-treated KO mice 
survived until ~P270 (97). The primary disadvantage to this treatment option is that 
hypoxia must be chronic, as intermittent hypoxia of 10 hours a day does not yield 




conditions, they die within a few days (97), therefore the practical application of 
hypoxia treatment for LS patients remains under investigation. This thesis will 
focus on two alternative treatments for LS that may have a more practical 
application, and may reduce or prevent some of the biochemical contributors to 
the pathology discussed above.  
Chapter 2 will investigate the utility of N-Acetylcysteine Amide (NACA), a 
precursor to the cellular antioxidant glutathione, in the treatment of LS. I propose 
that NACA will decrease oxidative stress by increasing the amount of glutathione 
in the cells, thereby decreasing ROS generation and protein oxidation. I also 
expect a decrease in succination, as the thiol group of NACA may react directly 
with available fumarate. Therefore, NACA may be dually beneficial in preventing 
both oxidant and metabolite derived cellular stress. 
Chapter 3 will investigate the use of microglial depletion in the Ndufs4 KO 
brain via PLX5622 (PLX). As the KO mice have an increased level of microglia 
compared to their WT littermates, I hypothesize that reducing the quantity of 
microglia will diminish the inflammation in KO brains. This will lessen the 







Figure 1.1 Electron Transport Chain (ETC). Flow of electrons and protons 














Figure 1.2 Complex I assembly. A) Displays the portion of the complex that 
provides the NADH dehydrogenase function. This portion includes Ndufs4. B) 
Assembly of the different subcomplexes contained in complex I. Ndus4 is located 
in the final subcomplex, allowing for the finalized structure of complex I and its 






Figure 1.3 Formation of S-(2-succino)cysteine (2SC). Protein thiols react with 
excess fumarate, forming an irreversible protein modification, S-(2-







Figure 1.4 Detection of Protein Succination in the Vestibular Nucleus (VN) 
of the Brainstem. VN extracts of Ndufs4 WT and KO mice was probed with anti-
2SC antibody to display a significant increase in succination of the VN of KO 
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Leigh syndrome (LS) is a mitochondrial respiratory chain disorder 
characterized by bilateral necrotizing lesions in the basal ganglia, thalamus and 
brainstem (BS), as well as seizures, ataxia, cognitive impairment, and stroke (44, 
45). Biochemically, lactic acidosis results from the accrual of pyruvate, as well as 
elevated levels of NADH, with increased lactate in cerebrospinal fluid associated 
with a severe disease course (43). As LS is commonly due to a mutation in 
complex I of the electron transport chain (ETC), the Ndufs4 knock-out (KO) mouse 
has been developed to model LS, displaying many of the common features of the 
human disease, including bilateral necrotizing lesions, ataxia, and respiratory 
distress (59). NADH:Ubiquinone oxidoreductase subunit S4 (Ndufs4) is an 
assembly protein that participates in the formation of the tertiary structure of 
complex I. The Ndufs4 KO mouse removes the NDUFS4 gene, resulting in the 
abolishment of the NADH dehydrogenase activity of complex I (56).   
 Mechanistically, the mitochondrial dysfunction observed is associated with 
increased oxidative stress, as evidenced by an increase in hydrogen peroxide 
(H2O2) and superoxide anion radicals in the mitochondrial matrix of fibroblasts from 
patients with confirmed LS (61) The fibroblasts from these patients were also 
observed to possess decreased antioxidant protection, including lower levels of 
enzymes involved in the “neutralization” of the reactive oxygen species (ROS) (61). 




in Ndufs4 KO mice vs WT (98), Koopman et al. displayed an increase in ROS of 
patients with a complex I deficiency, furthering this via a secondary experiment 
exposing increased ROS in Ndufs4 KO mice (99, 100). 
In addition to oxidative stress, we have recently described increased protein 
succination in the BS, olfactory bulbs (OB), and CB of the Ndufs4 KO mouse (14). 
Succination is derived from the spontaneous reaction of fumarate with the thiol 
group on protein cysteine residues, resulting in an irreversible chemical 
modification to form S-(2-succino)cysteine (2SC) (71, 72). Amplified levels of the 
metabolites fumarate and malate have previously been described in the urine of 
patients with mitochondrial diseases (73). In the Ndufs4 KO mice, this increase in 
fumarate is driven by the accumulation of NADH due to impaired complex I 
function, resulting in the inhibition of NAD+-dependent enzymes in the Krebs cycle 
(14).  
The tripeptide glutathione (GSH) functions as a potent antioxidant, as well 
as being necessary for the synthesis of other antioxidants, and exists in both 
reduced (GSH) and oxidized (GSSG) forms (101-103). Evidence has suggested 
that dysfunctional GSH homeostasis is implicated in various diseases including 
neurodegeneration and brain aging (104). N-acetylcysteine (NAC) has been used 
as a precursor to endogenous GSH, and has been established to have beneficial 
effects on diseases initiated by oxidative stress (105-109). However, NAC has low 
lipid solubility and tissue distribution, failing to provide significant antioxidant 
effects in vivo due to the loss of a proton by its carboxylic group at physiological 




acetylcysteine amide (NACA) was developed, replacing the carboxyl with an amide 
group. This modification allows NACA to cross membrane barriers, such as the 
blood brain barrier, and be more effective at lower concentrations (111).  
Recently, Liu et al. described an increase in oxidative stress and lipid 
accumulation as early disease markers in Drosophila models of mitochondrial 
dysfunction. To counter this, they demonstrated that NACA administration offered 
therapeutic benefit in both the Drosophila models and Ndufs4 KO mice. NACA 
administration for 7 days, beginning at postnatal day 21 (p21), delayed the onset 
of symptoms and reduced their severity throughout the lifespan of the Ndufs4 KO 
mice (105).  
 Fumarate reactivity with GSH has previously been described in models of 
fumarate hydratase deficiency where fumarate levels are significantly elevated and 
this has, in turn, increased production of ROS (112-114) Considering that excess 
fumarate may also directly react with the cysteine of NACA, we propose that NACA 
may offer additional benefit by decreasing protein succination in addition to 
reducing oxidative stress. Therefore, we hypothesized that extended, 14 day 
NACA treatment of 150 mg/kg/day in the Ndufs4 KO model might improve motor 
co-ordination in the mice, and reduce markers of mitochondrial stress including 
both oxidant and fumarate stress. 
2.2 Results   
Both NAC and NACA have previously been shown to increase the 




NACA may act in a cytoprotective manner, we exposed mature cortical neurons to 
dimethyl fumarate (DMF) for 5 hours. DMF rapidly induces a mild oxidative stress 
through the covalent modification of reduced GSH, which in turn activates several 
antioxidant response element genes (111, 115). Figures 2.1A & 2.1C demonstrate 
a pronounced decrease in the reduced GSH content following 5 hours of exposure 
to 100 µM DMF. Pre-treatment with either 5 mM NAC or NACA for 24 hrs 
completely protected the cells from the DMF induced depletion of GSH (Figure 
2.1A, 2.1C, (p<0.001)). Oxidized glutathione (GSSG) levels were also reduced 
upon DMF treatment, but not in the cells treated with NAC or NACA (Figure 2.1B, 
1D, (p<0.001)). These results confirm that DMF directly reduces cellular GSH 
content, leading to lower total levels of both GSH and GSSG. In addition to 
potentially increasing the GSH content, the pre-treatment with NAC and NACA 
would provide available thiols that DMF directly modifies, potentially sparing 
cellular GSH from direct modification. 
 Previously, a 7 day intervention with NACA in Ndufs4 knock-out (KO) mice 
versus wild-type (WT) littermates was shown to reduce the severity of clinical 
symptoms, as well as a delayed latency to fall from the rotarod (105). We 
hypothesized that extending NACA administration for a total of 14 days might 
further improve motor co-ordination skills in the Ndufs4 KO mice. Following 
weaning at 21 days of age, habituation and testing were performed between 23 
and 28 days of age. The mice were subsequently administered daily intraperitoneal 
injections of NACA for 14 days. The body weights of the KO mice decreased in 




mice, and there was no significant effect of NACA treatment on body weight 
(Figure 2.2).  
Fine motor co-ordination skills were evaluated on an inclined balance beam, 
with the untreated KO mice demonstrating significant impairment in their latency 
to traverse the beam between initial tests and those performed at the end of the 
study (KO Pre vs Post, Figure 2.3A, (p<0.001). Following the intervention period, 
KO mice were approximately three times slower than WT or WT + NACA in the 
average time to cross the beam, (WT vs KO, Post, Figure 2.3B, (p<0.001)), 
confirming a loss of fine motor skills. In contrast, KO + NACA mice did not display 
a significant variation in their speed (KO + NACA Pre vs Post, Figure 2.3A). The 
NACA treated KO mice traversed the beam significantly faster than the saline 
injected KO mice (KO vs KO + NACA, Post, Figure 2.3B, (p<0.05)).  
The number of paw slips (for any paw) that occurred while traversing the 
beam were also counted (Figure 2.3C). Both the KO and KO + NACA mice both 
had a significantly increased number of paw slips in comparison to the WT and WT 
+ NACA groups, indicative of impaired ability to balance. However, the KO + NACA 
mice had significantly fewer paw slips compared to the untreated KO mice (KO vs 
KO + NACA, Post, Figure 2.3C, (p<0.001)), indicating that NACA treatment also 
improved this aspect of subtle coordination and balance.  
 The co-ordination and endurance of the mice was also assessed in their 
latency to fall from the rotarod. Figure 2.4A demonstrates the difference in time to 




The KO and KO + NACA treated mice both fell from the rotarod significantly faster 
at the end of the study versus the initial testing period (KO pre vs post (p<0.001), 
KO + NACA pre vs post (p<0.001), Figure 2.4A). During the final trials, KO mice 
were only able to remain on the wheel for half the time of the WT mice (KO vs WT 
(p<0.001), KO + NACA vs WT (p<0.05), Figure 2.4B). However, unlike the balance 
beam, a significant improvement was not detected for the KO mice receiving NACA 
on the rotarod performance compared to untreated KO.  
 Since NACA treatment preserved neuronal GSH content in vitro (Figure 
2.1), an increase in the amount of reduced GSH in the olfactory bulb following 
NACA administration in vivo for 14 days was predicted. There was not a significant 
difference between the levels of GSH in WT versus KO mice (Figure 2.5A), 
although there was a slight trend for decreased GSH. This included a decrease 
between WT control mice and KO control, as well as KO + NACA mice having a 
lower concentration of GSH than KO control mice. There was also a trend for the 
GSSG:GSH ratio to be increased in the KO mice versus WT (Figure 2.5B). 
Unexpectedly, the KO + NACA olfactory bulbs contain less GSH than KO control 
(Figure 2.5A, p<0.05). GSH protein adducts in the BS of the mice were also 
assessed by non-reducing SDS-PAGE (Figure 2.6A). Densitometry was 
performed to determine the GSH adducts compared to amount of protein 
(Coomassie, Figure 2.6B). KO + NACA mice had a significantly decreased number 
of GSH protein adducts compared to untreated KO mice.   
 As our lab previously demonstrated that protein succination is associated 




(14), NACA was hypothesized to reduce protein succination in the KO mice via the 
thiol group directly reacting with fumarate. Figure 2.7 demonstrates a significant 
increase in 2SC protein adducts in the KO and KO + NACA mice versus the WT. 
NACA treated KO mice did not appear to have a significant reduction in the 
concentration of 2SC compared to KO controls. There was no change in the 
concentration of HNE protein adducts in the BS of WT mice as opposed to their 
KO littermates, signifying that there was not an increase in oxidative stress in the 
KO mice.  
 We used an in vitro model to determine if thiol supplementation could 
decrease excess fumarate and the amount of 2SC protein adducts. A fumarase 
knock-down (Fh KD) cell line was generated following transduction of N1E-115 
neuroblastoma cells with a lentiviral vector containing a fumarase shRNA. These 
cells were then differentiated into a neuronal phenotype and the effects on protein 
succination and mitochondrial respiration were characterized. The top panel of 
Figure 2.8A (2SC) displays the pronounced increase of 2SC in the Fh KD cells 
compared to scrambled control (Scr) cells, occurring alongside a significant 
decrease in the levels of fumarase protein. Synaptophysin confirms the successful 
differentiation of the knock-down cells into neurons (Figure 2.8A). Quantification of 
fumarate levels from both Scr and Fh KD cells demonstrated a ~17 fold increase 
in Fh KD compared to Scr cells, confirming that the increase in succination was 
driven by increased fumarate levels (Figure 2.8B (p<0.001)).   
Mitochondrial respiration was assessed in the Fh KD cells to determine the 




function. Figure 2.9A illustrates that the Fh KD cells had impaired oxygen 
consumption versus the Scr control. There were significant decreases in the basal 
respiration, ATP production, and maximal respiration in the Fh KD cells versus the 
Scr control (Figure 2.9B, (p<0.001)), see Appendix A for a representative 
mitochondrial respiratory stress profile). Considering the large increase in 
fumarate levels, the Fh KD and Scr control cells were treated with 5 or 10 mM NAC 
for 5 days during differentiation in an effort to reduce succination. While 2SC levels 
were significantly increased in Fh KD cells compared to Scr control after 5 days, 
this was not altered with the addition of NAC at either concentration, suggesting 
that fumarate reactivity with NAC thiols is limited (Figure 2.10A) (Scr vs Fh KD, Fh 
KD + 5 mM NAC, and Fh KD + 10 mM NAC, Figure 2.10B, (p<0.005)).  
 While the NACA treated mice had significant improvements in time required 
to transverse the balance beam, as well as number of paw slips, this was not 
associated with a visible decrease in protein oxidation or succination, nor an 
improvement in reduced glutathione levels. Therefore, we hypothesized that early 
intervention may be more important to this model, given the severity of the disease 
phenotype. Liu et al. treated Ndufs4 KO mice for 7 days with 150 mg/kg/day 
beginning at p21, and observed improvement in clinical signs, including a delay of 
symptom onset (105). In contrast, we treated the mice for longer (14 days), but did 
not initiate NACA treatments until ~p27-32. In order to determine how protein 
oxidation is affected, protein sulfenylation was measured via a sulfenic acid            
(S-OH) antibody. During oxidative stress, cysteine can undergo a reversible 




protein S-OH modifications function as a biomarker of redox signaling and 
oxidative stress (116, 117). BS and OB were removed from WT and KO mice at 
p21 (young) and p45 (old) and placed directly into a dimedone-containing buffer to 
stabilize the modification. Figure 2.11A displays a decrease in the amount of S-
OH present in the BS of old KO mice versus young. Due to the variability in the 
densitometry of the bands, while there is not a significant change, the visual 
decrease in the sulfenylation of old KO mice versus young (Figure 2.11B). 
2.3 Discussion 
Both NAC and NACA have been used successfully in several models to 
decrease oxidative stress (105-110). NACA offers improved utility over NAC for 
the treatment of neurological disorders since it has an improved ability to cross the 
blood brain barrier (110).The cysteine of NAC/NACA is a component of the 
tripeptide antioxidant, GSH, and we confirmed that NACA treatment in vitro 
enhanced the GSH content in neurons responding to DMF induced oxidative 
stress, similar to NAC (Figure 2.1A, 2.1C). Our lab has formerly shown that DMF 
directly modifies cysteine residues on proteins throughout the treated cells (115).  
 To date, only one previous study has shown that NACA administration 
specifically offers promise for the treatment of MDs (105). NACA administration for 
7 days in weaned Ndufs4 KO versus controls reduced the clinical severity of the 
disease. This was proposed to be related to the concomitant reduction in 
triglyceride accumulation in the VN and OB of the brain, regions in which 




syndrome (LS). Therefore, lipid droplet accumulation was proposed to be linked to 
the early presence of oxidative stress (105).  
In the current study, NACA administration for 14 days offered significant 
benefit in some behavioral parameters. The performance of the mice on the 
inclined balance beam exhibited the most promising results, with significant 
differences between the untreated KO and the KO + NACA groups in both the time 
to cross the beam and the number of paw slips (Figure 2.3). The success of the 
mice on the balance beam following NACA administration demonstrated that this 
treatment offered benefit in preserving fine motor control. However, while NACA 
had a positive effect on the fine motor skills, it did not increase their speed or 
endurance on the rotarod (Figure 2.4). This contrasts with the work of Liu et al., 
who found that the rotarod performance was improved at p30 following 7 days of 
NACA administration (105), but did not offer continued benefit at p40 or p60 after 
the treatment was stopped. Since our tests were performed at ~p24-28, it is 
possible that our studies were not performed within a suitable time frame to see 
beneficial effects of NACA treatment on this behavioral parameter. In addition, our 
measurements would also benefit from a larger sample size and we plan to 
perform further studies to support this. Overall, NACA administration appears to 
confer some benefit in preserving motor skills even as the neuropathology 
progresses, and should be considered further as an additional treatment to delay 
symptoms of LS in patients. 
Leigh syndrome has been linked to increased, chronic oxidative stress in 




levels would be lower in the olfactory bulbs of the KO mice, and that NACA 
administration might restore or preserve GSH similar to what we had observed in 
neurons in vitro (Figure 1A, 1C). We observed a trend for a decrease in GSH 
content in KO olfactory bulb versus WT control, as well as an increase in 
GSSG:GSH for these groups (figure 2.5). In contrast to our expectations, we 
observed a further decrease in GSH levels in the NACA-treated KO mice versus 
the untreated KO mice (Figure 2.5A). The ratio of GSSG:GSH was decreased in 
NACA treated mice, as were the presence of GSH protein adducts (Figure 2.5B, 
2.6), suggesting that NACA conferred some benefit in reducing protein oxidation, 
but does not drive large increases in GSH production in the KO mice. NACA 
administration did not result in a decreased production of HNE protein adducts in 
the brainstem (Figure 2.7); however, these were not detectably increased in the 
untreated KO brainstem versus WT, similar to our and other previous observations 
(14, 98).  
Our lab previously documented that protein succination (2SC) is increased 
in the brainstem of KO mice versus WT due to excess fumarate (14). We 
hypothesized that the administration of NACA would provide a source of free thiols 
that may react with fumarate and preserve protein thiols in the neuronal cells, 
offering additional therapeutic benefit. However, there was no difference in the 
2SC levels of KO mice versus KO + NACA (Figure 2.7). To further examine if 
NAC/NACA would directly reduce protein succination, we employed an in vitro 
model using fumarase knock-down (Fh KD) N1E-115 neurons. Fh KD neurons 




2SC levels (Figures 2.8). Notably, these cells also had significant decreases in 
mitochondrial respiration, as evidenced by decreased basal respiration, ATP 
production and maximal respiration (Figure 2.9). When treated with 5 mM and 10 
mM NAC for 5 days, there was no reduction in protein succination (Figure 2.10). 
Therefore, it is possible that fumarate is not sufficiently reactive with the thiols of 
NAC/NACA in vitro and in vivo to provide sufficient protection. Endogenous 
fumarate is known to react with low pKa thiols (118), however, the pKa of 
NAC/NACA is ~9.6 and 8.5 respectively (119-121). Therefore, NACA may not be 
sufficiently reactive with fumarate to provide sufficient protection in this model. 
Previous work in fumarase deficient cancer cell lines, where fumarate is elevated 
to milimolar levels, did demonstrate some reactivity of fumarate with reduced 
glutathione (122, 123), however, the extent of the modification was low and may 
only occur when fumarate levels are dramatically elevated.  
Ndufs4 KO mice suffer a severe pathology, developing symptoms around 
p21 with death occurring at ~p50 (58). Considering that Liu et al. started NACA 
treatment at p21 (106), whereas we began treatments at ~p24-28, we 
hypothesized that the ~1 week later initiation of treatment may have a large impact 
on the ideal window for NACA intervention. In order to test the concept that the 
mice must start treatment early to reduce oxidative stress-related pathology, we 
used the brainstems of p21 (young) and p46 (old) mice to detect the levels of 
sulfenic acid, a product of protein thiol oxidation. We predicted that the younger 
KO mice might have increased levels of protein sulfenylation versus the older KO 




in the young and old KO mice, with substantial decreases in select protein in the 
older mice. This suggests that increased protein oxidation occurs early in the 
brainstem of the Ndufs4 KO mouse, and may be contributing to the neuropathology 
that these mice develop, even if changes in oxidative stress markers e.g. HNE 
cannot be detected later. Therefore, our results suggest that NACA intervention in 
the Ndufs4 KO model of Leigh Syndrome will offer maximal benefit if administered 
early and for longer periods across the mouse lifespan. This also emphasizes the 
importance of early confirmed diagnosis in human patients so that advantageous 


















Figure 2.1 Glutathione Fluorescence Assay performed on neuronal cells 
treated with DMF, NAC, and NACA. A,C) Amount of reduced glutathione in 
neuronal cells normalized to protein content. B,D) Amount of oxidized glutathione 
normalized to protein content. A and B were treated with 5 mM NAC for 24 hours 
followed by 100 µM DMF for an additional 5 hours. C and D were treated with 5mM 
NACA for 24 hours with a further treatment of 100µM DMF for 5 hours prior to 
scraping (DMF n=5, Control, NAC, NACA, NAC + DMF and NACA + DMF n=6, 

































Figure 2.2 Body weight of mice. Average body weight of the mice in each 
experimental group, where week 0 is the weight at the beginning of testing, and 
the final weight (week 3) was measured prior to the termination of the study (WT 






Figure 2.3 Balance beam testing performed on wild-type (WT) and knock-out 
(KO) mice before and after NACA injections. A) The average amount of time 
taken for mice (by treatment group) to cross the inclined balance beam before and 
after drug administration (***p<0.001 vs pre KO). B) Average period of time for 
mice to transverse beam after treatment (*p<0.05 vs WT, **p<0.01 vs WT, #p<0.05 
vs KO). C) Number of paw slips by each treatment group during one run across 
the inclined beam after NACA or saline treatments (*p<0.05 vs WT, **p<0.01 vs 
WT, ### p<0.001 vs WT; n=11, 4, 7 and 6 for WT, WT + NACA, KO and KO + 






Figure 2.4 Rotarod testing performed on NACA injected mice. A) The average 
amount of time for the mice to fall from the rotarod before and after drug 
administration (maximum of 300 seconds) (**p<0.01 for pre of same treatment 
group). B) The final times for mice to fall, averaged by their treatment group (* 
p<0.05 vs WT, **p<0.01 vs WT; n=11, 4, 7 and 7 for WT, WT + NACA, KO and KO 






Figure 2.5 Glutathione Fluorescence Assay of olfactory bulbs following 
NACA treatment. A) Reduced glutathione concentration in the OB of Ndufs4 mice 
normalized to protein content (*p<0.05 compared to KO mice). B) The ratio of 
oxidized (GSSG) to reduced GSH (statistics performed via one-way ANOVA. WT 













Figure 2.6 Glutathione analysis of mouse brainstem following treatment.      
A) 40 µg of protein from the BS was run on a gel under non-reducing conditions 
and probed with the GSH primary antibody (top panel). Coomassie displays 
loading of the protein (bottom panel). B) Densitometry analysis, via Image J 
software, of the GSH adducts normalized to the Coomassie; demonstrating 
normalization to protein content (*p<0.05 compared to KO mice, statistics 






Figure 2.7 Protein analysis of brainstem from mice after NACA. 30 µg of BS 
protein run via SDS-PAGE. The top blot, 2SC, presents the intensity of the 
modification, in a multitude of proteins, as it increases in Ndufs4 KO mice versus 
WT, without exhibiting a change between KO and KO + NACA BS samples. HNE 
displays no significant change between the groups (HNE panel). The Coomassie 






Figure 2.8 Effects of Fh knock-down (KD) on protein succination, neuronal 
differentiation, and intracellular fumarate concentration. A) 20 µg protein from 
scrambled (Scr) and Fh KD N1E-115 differentiated cells probed with anti-2SC 
(2SC panel). Increased succination is observed for a large number of proteins in 
the Fh KD cells. Confirmation of the fumarase shRNA effectiveness to decrease 
fumarase expression is also shown (fumarase panel). Differentiation of the cells to 
a neuronal phenotype was confirmed by the expression of the presynaptic marker 
synaptophysin (synaptophysin panel). Even loading of the lanes was confirmed by 
Coomassie staining (Coomassie panel). B) Fumarate concentration in extracts 
from Fh KD is increased more than 17-fold compared to Scr N1E-115 cells. (n=5, 















Figure 2.9 Effects of Fh knock-down on mitochondrial respiration.                     
A) Respiratory profile of Fh KD and Scr N1E-115 neurons measured using the 
Seahorse XF analyzer. Compounds were added at the indicated arrows to assess 
mitochondrial function (**p<0.01 vs Scr). B) Basal respiration, proton leak, oxygen 
consumption coupled to ATP production, maximal respiration, spare capacity, and 
non-mitochondrial respiration were calculated following the addition of oligomycin, 
FCCP, and rotenone/antimycin A (Rot + Ant), (**p < 0.01 vs. Scr control, n=5,           
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Figure 2.10 2SC levels of fumarase knock-down cells treated with NAC. A) 30 
µg of protein from Fh KD and Scr N1E-115 cells treated with 5 mM and 10 mM 
NAC was probed with anti-2SC, demonstrating increased succination in the KD 
cells. Coomassie panel presents protein loading. B) 2SC levels were normalized 
to Coomassie via Image J and graphed with Sigma Plot. This demonstrated 
significantly increased succination in Fh KD cells, compared to Scr, but no 
significant change when cells were treated with NAC compared to control 






Figure 2.11 Detection of protein sulfenylation in the brainstems of young and 
old wild-type and knock-out mice. A) 20 µg of protein from the BS of young and 
old WT and KO mice run via SDS-PAGE, and probed with anti-S-OH. Actin exhibits 
protein loading (actin panel). B) S-OH content normalized to actin via densitometry 
performed on Image J. While there were no significant decreases due to the 
variability in band intensity, there was a pronounced trend for decreased 







MICROGLIAL DEPLETION IN A MOUSE MODEL OF LEIGH 
SYNDROME 
3.1 Introduction
 Microglia are the principal immune cells of the central nervous system 
(CNS), and compose approximately 12% of the total cells in the CNS (124). 
Microglia play a crucial role in limiting damage from injury, for example, 
phagocytosing aggregating peptides that may be toxic and limiting plaque 
formation (124-126). In other situations, however, this “beneficial” response may 
lead to chronic inflammation in the brain, contributing further to the disease (124, 
127). During neuroinflammation, the microglia secrete proinflammatory cytokines, 
including IL-1β, IL-6 and TNFα that may exacerbate neuronal damage or injury 
(128, 129). Rice et al. induced lesions in the brain of mice and discovered that 
activated microglia increased the level of inflammation, which was associated with 
impeded recovery. Once lesions were present, removal of the microglia resulted 
in improved scores on the elevated plus maze, in addition to reversing the lesion-
induced pro-inflammatory release, including B2m and Bax. While microglia prove 
beneficial during a diphtheria toxin-induced neuronal lesion, their continued 




 Colony stimulating factor 1 receptor (CSF1R) is a cell surface receptor 
located on macrophages, microglia and osteoclasts (130). CSF1, a natural ligand 
of the CSF1R, is a growth factor that regulates the proliferation, differentiation, and 
survival of these cell types. Microglia are the only cells in the brain that express 
CSF1R, and CSF1R knock-out mice are devoid of microglia in the brain (130, 131). 
Recently, a pharmacological approach was developed that specifically depletes 
microglia via inhibition of CSF1R signaling (131, 132). Spangenberg et al. 
eliminated approximately 80% of the microglia in a mouse model of Alzheimer’s 
disease using a CSF1R inhibitor, resulting in the rescue of dendritic spine loss, 
preventing neuronal loss, reducing neuroinflammation, and improving contextual 
memory (133). CSF1R inhibitors have also been used to improve radiation-
induced cognitive deficits in mice treated with irradiation for brain cancer (134). 
 PLX5622 (PLX) is a CSF1R inhibitor proven to eliminate up to ~99% of 
microglia in the nervous system of mice receiving it orally over several days to 
months (124, 135). Acharya et al. treated mice for 3 days with 1200 mg/kg of PLX, 
resulting in 95% reduction in microglial number (134). A lower concentration of 300 
mg/kg was fed to 3xTg-AD mice, a model of Alzheimer’s disease, for 7-21 days 
and resulted in a 30% reduction of microglial number and improved cognition 
(124). Results were obtained using C57BL/6J, a common black laboratory mouse, 
discovering that both the 300 mg/kg and 1200 mg/kg doses of PLX achieved 
comparable microglial reductions (136). Ndufs4 KO mice have been observed with 
enhanced microglial activation, particularly in regions suffering from necrotizing 




increase simultaneously (59). Ionized calcium binding adaptor molecule 1 (Iba-1) 
is a protein expressed solely in microglia, regulating their function (137, 138). We 
hypothesized that PLX administration to deplete microglia and reduce 
neuroinflammation in the Ndufs4 KO mice may reduce microgliosis and the motor 
co-ordination deficits associated with the neuropathology. In addition, we have 
recently observed that activated macrophages (lipopolysaccharide-stimulated) 
have pronounced increases in fumarate and protein succination (unpublished 
data). Therefore, we hypothesized that PLX-mediated removal of microglia (the 
macrophages of the CNS) may result in a decrease of protein succination in the 
KO mice. Alternatively, it may increase neuronal survival and also prevent 
increased succination in neuronal cells. Thus, we investigated diets containing 
both the 300 mg/kg (low dose) and 1200 mg/kg PLX (high dose).  
3.2 Results 
PLX5622 (PLX) is a CSF1R inhibitor demonstrated to eliminate microglia 
(124, 134-136), and these experiments represent the first use of this compound in 
a mitochondrial disease model to decrease neuroinflammation. In this study, two 
trials were performed, one using 1200 mg/kg PLX in the diet for 3 days, and the 
other with 300 mg/kg PLX for 14 days. Previous work has been conducted in 
murine models for a duration of 1-3 months, however, shorter exposures (up to 2 
weeks) are necessary in the Ndufs4 KO model as they have such a severe disease 




 A specific anti-Iba-1 was used for immunoblotting to assess the levels of 
Iba-1 in both the brainstem (BS) and olfactory bulb (OB) of WT and KO mice 
(Figure 3.1A). While there was a slight increase in Iba-1 concentration in BS from 
WT mice versus KO, the OB demonstrated a significant increase in Iba-1 in the 
KO mice versus their WT littermates, confirming the microgliosis. To determine, 
more specifically, if the mice would be treated at an age where KOs already 
contained increased microglia, early (p24-26) and mid (p46) KO mice OB were 
compared to early (p24-26) and late (p60-63) WT mice OB. Iba-1 probing 
demonstrated a significant difference in both of the KO age groups versus the WT 
controls (WT early versus KO early and mid (p<0.05); WT late versus KO early 
and mid (p<0.001), Figure 3.1 B, 3.1C), confirming that microgliosis is present as 
early as p24 in the KO mice.  
Mice were to be treated with PLX for 3 days (1200 mg/kg) or 14 days (300 
mg/kg) beginning at approximately p22-24. When administered the 1200 mg/kg 
dose, Ndufs4 KO mice suffered rapidly declining health, including respiratory 
distress and limited-to-no motor movement. This lead to termination of the study 
at three days and the determination that Ndufs4 KO’s pathology is too severe to 
survive on the 1200 mg/kg dose of PLX. The 14 day, 300 mg/kg PLX trial also 
triggered a worsening in clinical symptoms, leading to an early cessation of the 
experiment. A PLX-treated mouse died 2 days prior to the planned termination of 





Following the PLX treatment of the WT and KO mice, the BS of the 3 day 
(1200 mg/kg diet) and 13 day (300 mg/kg diet) were examined to determine if Iba-
1 levels had been altered by either treatment (Figure 3.2A). While several bands 
were apparent on the Iba-1 blot, the band ~17kDa appeared to be more intense in 
the untreated WT group versus the KO mice, which is inconsistent with our 
previous observations in Figure 3.1, and the work of others (44). PLX treatment of 
the WT mice appeared to significantly decrease Iba-1 levels (Figure 3.2B, 
p<0.001). However, since the levels of Iba-1 could not be accurately assessed in 
the whole brainstem across all groups, despite multiple attempts, we could not use 
this to determine if PLX treatment had been successful in these mice. 
Unfortunately, the olfactory bulbs from these mice were used for a separate 
experiment and were not available for protein analysis. 
 Due to the fact that activated microglia may show increased fumarate levels 
and protein succination, we hypothesized that decreasing the heightened 
population of microglia in KO mice would decrease the levels of 2SC present. 
Figure 3.3A displays the levels of 2SC in the BS of mice from the 3 day PLX study. 
There was no significant difference in untreated KO mice, and those receiving PLX 
(Figure 3.3B). BS protein was also immunoblotted and probed with anti-2SC for 
the 13 day treated mice (Figure 3.4A). As expected, 2SC levels were again 
increased in the untreated KO versus WT (p<0.01), however there was no 
significant change in 2SC levels between treated and untreated KO groups (Figure 
3.4B). Note: one of the PLX treated Ndufs4 KO mice was included on the blot and 




subsequently learned that this mouse had died prematurely and had been 
refrigerated prior to protein calculation. This lane was not included in normalization 
or statistical analysis. Overall, the data suggested that 2SC levels were not 
significantly altered in the PLX treated KO mice versus untreated KO; however, 
the sample size of remaining mice in the study was limited. 
 Since the mice did not have any improved survival on the 300 mg/kg PLX 
containing diet for 14 days, we performed a trial on WT mice in order to determine 
a shorter period of time that would still significantly reduce the amount of microglia. 
WT mice were given 300 mg/kg PLX chow for 3, 5, or 7 days, and the hippocampus 
was used for Iba-1 probing. The hippocampus was selected as this region exhibits 
a change in microglial content when mice are fed PLX (124). Hippocampal Iba-1 
levels showed significant reduction for 3, 5 and 7 days (control versus 3, 5 and 7 
day PLX, Figure 3.5A, 3.5B, (p<0.001)). While all three treatments times displayed 
reductions in Iba-1, we decided to perform a 7 day treatment with PLX, as it 
demonstrated the greatest change from the control mice.  
 Since we observed negative effects on the mice when we attempted to 
remove all of the microglia over 13 days, we hypothesized that a minimal period of 
7 days on PLX, followed by another 7 days for repopulation, would be more 
beneficial for the KO mice. We considered that repopulation of the affected area 
with healthy microglia might prove beneficial for the removal of dying neurons in 
the Ndufs4 KO model, and that the microgliosis that is present may be the result 




Behavioral tests were performed the prior to PLX administration (day 0), 
after PLX administration (day 6-7), and finally after repopulation (day 12-13). The 
rotarod was used to assess the speed and endurance of the mice, in addition, we 
considered time spent “cart-wheeling”, in which the mice are not continually 
running on the wheel, but holding-on and allowing the wheel to spin them around, 
thereby breaking from the exercise. The time that the mice were able to run on the 
wheel was recorded, minus time spent cartwheeling. Figure 3.6A displays an 
average time for the treatment groups during each testing cycle. The WT + PLX 
mice had a subtle decrease in time spent on the rotarod directly after drug 
administration, but were able to run longer after the repopulation period. During 
the repopulation period, there was a significant decrease in time to fall between 
WT mice versus KO and KO + PLX (WT vs KO and KO + PLX, Figure 3.6B, 3.6C, 
3.6D, (p<0.01)). There were no statistical significances discovered between KO 
and KO + PLX mice at any time point tested.  
An inclined balance beam was used to test the speed and fine motor 
coordination of the mice. The time for mice to transverse the meter-long beam was 
recorded, along with the number of paw slips during the test. There was a 
significant increase in the time to cross for WT + PLX following PLX administration 
(p<0.05) and after repopulation (p<0.01) (Figure 3.7 A, C, and D). There were 
significant differences between WT mice and both KO and KO + PLX directly after 
treatment (WT vs KO and KO + PLX, Figure 3.7B, (p<0.05)). WT versus KO mice 




with p<0.01. However, no statistical significance was found between KO and KO 
+ PLX, following the repopulation period.  
Paw slips were difficult to determine during the repopulation period due to 
two mice not being able to keep their paws on the top of the beam, therefore only 
one mouse in the KO group and two in KO + PLX could be considered. Figure 3.8A 
demonstrates a continually increasing number of paw slips in the KO + PLX group, 
while the other treatment groups are significantly lower. There was an increase in 
paw slips in the KO + PLX immediately post-treatment versus prior to treatment 
(KO + PLX pre vs post, Figure 3.8C, (p<0.05)). The number of paw slips in the 
testing period after microglial repopulation was significantly increased over both 
pre-treatment and post-treatment (pre vs repopulation (p<0.001), post vs 
repopulation (p<0.05), Figure 3.8C). Immediately after the 7 day treatment, KO + 
PLX had a significantly increased number of paw slips in comparison to WT mice 
(WT vs KO + PLX, Figure 3.8B, (p<0.05). The difference between KO + PLX and 
WT was increased further after repopulation, as well as a significant difference 
between KO and KO + PLX (WT vs KO + PLX (p<0.001), KO vs KO + PLX 
(p<0.05), Figure 3.8B, 3.8D). The data suggested that the number of paw slips 
increased following PLX treatment in the KO mice, but not in WT animals, although 
the limited sample size is a source of variability in these measurements.  
Ndufs4 KO mice are naturally smaller and weigh less than their WT 
counterparts. WT and WT + PLX mice had significantly increased body weight from 
day 0 (beginning of PLX) until day 14 (sacrifice) (WT day 0 vs day 14 (p<0.01), WT 




not show significance. During the last four days of the study (day 11 to 14), KO 
and KO + PLX mice both displayed weight that was significantly lower than their 
WT counterparts (Figure 3.9B). KO + PLX mice weighed less than control KO mice, 
and showed a greater significance compared to both WT groups.  
Protein analysis was completed on the olfactory bulb of the mice, probing 
for both 2SC and Iba-1. Probing for microglial marker content in the OB with Iba-1 
showed, that while there was a slight increase in KO + PLX mice versus KO, there 
was no significance (Figure 3.10A, 3.10B). This confirmed that microglial 
repopulation occurred, however, the limited number of mice in the study prevented 
a post-treatment analysis of Iba-1 at 7 days. Anti-2SC immunoblotting displayed a 
significant increase in KO and KO + PLX mice compared to WT mice (WT vs KO 
and KO + PLX, Figure 3.10C, 3.10D, (p<0.001). However, there was no difference 
between KO and KO + PLX, suggesting that treatment did not alter succination 
levels in the newly repopulated microglia.  
3.3 Discussion 
 PLX treatment has been shown to remove up to ~99% of microglia following 
a 21 day exposure in dietary chow (136). In this study we first confirmed increased 
microgliosis in the olfactory bulbs of KO versus WT mice (Figure 3.1), however, 
Iba-1 levels could not be reliably detected with the antibody in the brainstems of 
the 3 day and 13 day PLX treated mice (Figure 3.2). Unfortunately, the olfactory 
bulbs were not available for Iba-1 analysis in these mice, as this region appears to 




while we could not reliably confirm that the drug had resulted in microglial 
clearance, it was evident that the microglial removal did not confer any additional 
benefit on survival of the KO mice as there was a steep decline in the severity of 
clinical symptoms. The 3 day treated mice had respiratory difficulties, highly 
impaired motor coordination and muscle strength, resulting in the necessity of 
chow being placed beside the mice, as they were not able to feed otherwise. While 
Ndufs4 KO mice treated for 13 days were slightly healthier than those receiving 
PLX for 3 days, their condition was significantly harsher than that of untreated 
mice, ultimately resulting in premature death of one mouse. For this reason the 
planned 14 day PLX intervention had to be terminated early at 13 days.  
Despite the apparent lack of benefit, we were still interested to determine if 
microglial removal had resulted in altered succination profile in the brain. A recent 
collaboration with another laboratory highlighted that activated macrophages may 
have increased levels of protein succination in the brain during neuropathology in 
the KO mice. To determine if PLX administration and microglial removal reduced 
succination, we performed immunoblotting for 2SC in the 3 day and 13 day treated 
mice (Figures 3.3 and 3.4). There was a trend for a slight reduction in protein 
succination in the PLX treated KO mice versus untreated KO, however, it is difficult 
to determine if this was due to a limited effect of PLX to remove microglia, or if 
succination was significantly altered. It is possible that the (dying) neurons contain 
higher levels of succinated proteins and therefore a decrease in the microglia may 




warrant further investigation in a study where reduced microglial content can be 
confirmed.  
 Since 14 days on PLX was confirmed to be too long a period for our mice, 
a time course was set up to discover if administration for 3, 5, or 7 days would be 
a better alternative. Using the promising elimination data obtained in Figure 3.5, 
we further hypothesized that administration of PLX for 7 days, followed by allowing 
7 days for ‘new’ microglial repopulation would be a better strategy. This would 
remove the unhealthy microglia that they have difficulty being cleared from the 
lesion, and allow new, healthy microglia to surround the lesion and help 
phagocytose the neuronal debris. We anticipated that this would result in a slightly 
decreased number of microglia in KO + PLX versus KO control mice, and hoped 
to see increased motor coordination during behavioral tests if survival was 
positively impacted.  
 The test of speed and endurance, rotarod, demonstrateded the KO and KO 
+ PLX mice had approximately identical performance through the three testing 
periods. Both untreated and treated KO mice fell from the rotarod earlier in each 
subsequent testing period (Figure 3.6). Balance beam also measured speed, as 
well as fine motor coordination reflected similar results, with both taking longer to 
transverse the beam (Figure 3.7). The PLX treated KO mice appeared to have 
more paw slips (Figure 3.8), however, there was a lot of variability in this 
measurement and we were severely hindered by the small sample size in the 





 Protein analysis of the 7 day on/7 day off PLX mice was performed to 
determine Iba-1 levels in the brain after the treatment. Unfortunately, we did not 
have sufficient mice to sacrifice a separate group at 7 days, immediately after the 
drug had been administered as we hoped to record more positive behavioral 
changes and focused on this with this particular group of mice. Iba-1 displayed an 
increase in microglia of KO + PLX versus KO mice, although this was not 
significant (Figure 3.10). Elmore et al. also experimented with withdrawal of PLX 
and showed microglia exhibiting a larger morphology versus control at 3 and 7 
days post-PLX. They also displayed a higher concentration of microglia at 7 days 
after treatment, while by 14 days, the population of microglia was almost normal 
(130). Both increased size and number of microglia could explain the increase in 
Iba-1 we observed, as well as 2SC levels remaining unchanged between the 
untreated KO and KO + PLX groups. We proposed that the KO + PLX KO mice 
would contain fewer succinated proteins because the unhealthy microglia would 
be absent, along with their heightened level of succination. However, the increased 
number of microglia may result in a relatively unchanged amount of protein 
succination, even if the level of succination in individual cells is decreased.  
 Overall, these preliminary studies with PLX demonstrate that profound 
decreases in microglial number do not appear to positively impact behavior or 
survival in the Ndufs4 KO model similar to studies in other disease models. This 
may be related to the severity of the neuropathology in the Ndufs4 KO mice, and 
the fact that the microglia are performing a necessary function to remove dying 






Figure 3.1. Brainstem versus olfactory bulb and effects of aging on 
microglial concentration. A) Trial of brainstem (BS) vs olfactory bulb (OB) used 
40 µg protein from respective areas to display differences in Iba-1 between WT 
and KO mice. B) Effects of aging on Iba-1 levels in 40 µg of protein from OB (WT 
early (p24-26), KO early (p24-26), KO mid (p46) and WT late (p60-63)). C) 
Normalization of age Iba-1 blot to Coomassie (*p<0.05 vs WT early; ###p<0.001 






Figure 3.2 Microglial concentration in mice treated with PLX for 3 and 13 
days. A) 40 µg BS protein, run using SDS-PAGE and probed for Iba-1 for WT and 
KO mice treated with PLX for 3 and 13 days (middle band, 17kDa) (lanes 1-5 = 
untreated WT, lanes 6-9 = WT + 3 day PLX, lanes 10-12 = WT + 13 day PLX, lanes 
13-15 = KO + 13 day PLX, lanes 16-19 = KO + 3 day PLX, lanes 20-23 = untreated 
KO). B) Iba-1 of 3 versus 13 day PLX normalized to Coomassie (**p<0.01 vs WT; 
***p<0.001 vs WT; ##p<0.01 vs WT-3; WT n = 5, WT-3 n = 4, WT-13 n = 3, KO–






Figure 3.3 Differences in succination of the brainstem with 3 day PLX 
treatment. A) 30 µg BS protein from 3 day PLX treated mice was probed with anti-
2SC. B) Normalized 2SC levels to Coomassie (***p<0.001 vs WT; WT n = 2, KO 
n = 2, KO + 3 day PLX n = 4, WT + 3 day PLX n = 4; Statistics performed via one-






Figure 3.4 Determination of 2SC content in the brainstem of 13 day treated 
PLX mice. A) 40 µg protein was run via SDS-PAGE, and probed with 2SC 
antibody (+ is positive control, Fh KD cell protein). B) Densitometry performed on 
2SC with Image J and normalized to Coomassie (*p<0.05; **p<0.01. Statistics via 
one-way ANOVA,   SEM). *The third lane in KO + PLX was not used for 
normalization or statistics, as this mouse died prior to the others, and was not 







Figure 3.5 Test for the efficiency of PLX in eliminating microglia over 3, 5, 
and 7 days. A) 40 µg protein from the hippocampus of WT mice treated with PLX 
for increasing variables of time was probed with anti-Iba-1 to test for microglial 
presence. B) Normalized amount of hippocampal Iba-1 to Coomassie (***p<0.001 






Figure 3.6 Rotarod testing of mice treated with PLX for 7 days followed by a 
7 day repopulation period. A and B) Average time to fall for mice during pre, 
post and repopulation periods (**p<0.01 vs WT repopulation). C) Average time to 
fall for each treatment group at the 3 time points. D) Average time for mice to fall 
after the 7 day repopulation period (**p<0.001 vs WT, WT n = 4, WT + PLX n = 4, 






Figure 3.7 Balance beam behavioral testing for mice treated with PLX 7 days 
on and 7 days off. A and B) Average times of treatment groups for pre-, post- 
and repopulation periods (*p<0.05 vs WT post-treatment; #p<0.05 vs WT 
repopulation; ##p<0.01 vs WT repopulation). C) Average time to converse the 
beam of each treatment group, at the three testing stages (*p<0.05 vs KO + PLX 
pre; **p<0.01 vs KO + PLX pre). D) Time for the groups to cross the beam during 
the final repopulation testing (*p<0.05 vs WT; **p<0.001 vs WT, WT n = 4, WT + 
PLX n = 4, KO n = 2, KO + PLX n = 3; statistics performed in Sigma Plot via two-






Figure 3.8 Paw slips of mice while crossing the balance beam. A and B) 
Average number of paw slips during each testing period (#p<0.05 vs WT post; 
***p<0.001 vs WT repopulation; $p<0.05 vs KO repopulation). C) Average paw 
slips for treatment groups during the 3 tests (*p<0.05 vs KO + PLX pre; ***p<0.001 
vs KO + PLX pre; #p<0.05 vs KO + PLX post). D) Paw slips during repopulation 
testing (***p<0.001 vs WT; #p<0.05 vs KO, WT n = 4, WT + PLX n = 4, KO n = 1, 






Figure 3.9 Weight of mice from initial treatment exposure (Day 0) to date of 
sacrifice (Day 14). A) Body weight of mice (**p<0.01 vs WT Day 0; ##p<0.01 vs 
WT + PLX Day 0) B) Body weight of mice by individual date (#p<0.05 vs WT + 
PLX; *p<0.05 vs WT; **p<0.01 vs WT; ***p<0.001 vs WT). (WT n = 4; WT + PLX 
n = 4; KO n = 2; KO + PLX n = 4; statistics via two-way ANOVA,  SD).
Day 0    Day 5    Day 7   Day 11   Day 13   Day 14 






Figure 3.10 Protein analysis of olfactory bulb samples obtained from 7 day 
PLX, 7 day repopulation mice. A) 40 µg OB protein was loaded and run with 
SDS-PAGE and probed with Iba-1 antibody. B) Iba-1 blot normalized to 
Coomassie using Image J software. C) 30 µg protein was loaded and probed with 
2SC using Coomassie for protein loading control D) 2SC blot normalized to 
Coomassie via Image J (**p<0.01 vs WT; ***p<0.001 vs WT; statistics performed 






Due to the visual difference in sulfenylation of KO young versus old mice, I 
believe that it would be good to begin administering NACA at 21 days, as 
performed in Liu et al. We would continue to treat for the full 14 days in an effort to 
enhance the results that they observed, including a delay in the onset of 
symptoms, as well as decreasing their severity. Since we believe that the oxidative 
stress begins early in life, and does not seem as predominant later, treating this 
early could potentially increase the longevity of the mice, as well as their standard 
of living.  
 We proved that there was a significant decrease in the number of microglia 
when WT mice were treated with PLX for 7 days, thereby predicting that a 7 day 
period after this would allow new, healthier microglia to repopulate and assist the 
brain. The next experiment would build on the 7 days on/7 days off experiment we 
already completed. More mice would be used in order to obtain additional testing 
groups, as well as adding to the data from the current mice. These groups would 
include mice both sacrificed directly after the 7 day treatment period and pushed 
to survive an additional 7 days past the current repopulation period. Protein 




the proficiency of PLX5622 in this mouse model. In addition, 2SC levels, from all 
four time points, would be measured to determine if the new microglia are 
‘healthier’ in terms of succination. Besides the protein analysis, we would take 
slices of the BS, particularly the VN, and the hippocampus. Immunohistochemistry 
of sections from before PLX treatment, immediately post-treatment, after 7 days 
repopulation, and 14 days repopulation would allow us a visual of the number and 
size of microglia present, when staining with Iba-1. While immunoblotting allows 
us to see the amount of certain proteins, this will allow visualization of where they 
are located and if size or shape has changed due to the treatment. That way we 
would be able to determine if results observed in Elmore et al. (126) apply to our 





Materials. Unless otherwise noted, all chemicals were purchased from Sigma 
Aldrich (St. Louis, MO). Anti-2SC antibody was prepared by Eurogentec (Fremont, 
CA). Tween-20 and Criterion™ TGX™ Precast Gels were from Bio-Rad (Hercules, 
CA). Polyvinylidene fluoride (PVDF) was purchased from GE Healthcare (Fairfield, 
CT). L-glycine and sodium dodecyl sulfate (SDS) were purchased from Fisher 
Scientific (Waltham, MA). N-acetylcysteine amide (NACA, (R)-2-Acetamido-3-
mercaptopropanamide) was synthesized by Matrix Scientific (Columbia, SC). 
PLX5622 was generously provided by Plexikkon Inc. in standard chow prepared 
by Research Diets Inc. (Berkeley, CA) (300 mg/kg D11100406i) (1200 mg/kg 
D11100404i).  
Animal Model. All animal use described in this and other sections was consistent 
with the guidelines issued by the National Institutes of Health and were approved 
by the University of South Carolina Institutional Animal Care and Use Committee. 
NDUFS4 knock-out mice were obtained from Dr. Richard Palmiter (University of 
Washington, WA). The mice were bred and pups were genotyped at 3 weeks. WT 
and KO mice in the NACA experiment were treated with intraperitoneal injections 
of 150mg/kg/day NACA for 14 days, beginning at approximately p26. At the 
termination of the studies mice were anesthetized by isoflurane prior to 




mg/kg PLX for 3 days or 300 mg/kg PLX for 7 or 13 days. The mice participating 
in the 7 day on/7 day off PLX study underwent behavioral testing prior to 7 days of 
300 mg/kg PLX, followed by a 7 day repopulation period before being anesthetized 
by isoflurane, followed by decapitation. 
Behavioral Testing 
Balance Beam. Mice underwent training 3 days prior to testing, as well as 
habituation 30-60 minutes before the test. Mice were placed at the end of a 
one meter long beam with a width of 7 mm. The beam was placed at a 4 
degree angle with a black box at the opposite end containing food and 
bedding. The mouse was allowed 20 seconds to sit in the box before 
crossing the beam. Between trials, mice were allowed an additional 15-20 
seconds to recuperate in the box. Total number of paw slips and the time 
taken to cross were both measured during the 4 times the mouse crossed 
the beam. The three best times were used for statistics.  
Rotarod. As stated above, mice were trained 3 days before testing, and 
habituated in the room. The speed on the rotarod was increase 4-40 rpm 
over a span of 5 minutes. Mice were tested 5 times each, with four of those 
used for statistics. In PLX experiment, mice were recorded, and 
cartwheeling time taken into account. Cartwheeling occurs when the mouse 
holds onto the wheel and circles instead of running.  
Protein Extraction from Brain Tissue. Brainstem, olfactory bulb, or hippocampus 




with 2 mM Sodium Fluoride, 2 mM Sodium Orthovanadate, and 1/1000 protease 
inhibitor cocktail (RIPA+ buffer) and sonicated 2 times for 7 seconds each. The 
tissue was incubated on ice for 10 minutes and centrifuged at 5000 rpm for 10 
minutes at 4°C. A supernatant and pellet were then visible. The supernatant was 
extracted and acetone (9x volume) was then added to each supernatant sample. 
The samples were vortexed, allowed to sit on ice for 10 minutes and then 
centrifuged at 2000 rpm for 10 minutes at 4°C. The acetone was removed 
completely and the protein pellets were re-suspended in 125-200 µL of RIPA+ 
buffer and sonicated for 10 seconds each. The protein concentration was 
determined using the Lowry method (140). 
Cell Culture and Viral Transduction. The lentiviral vectors were prepared by the 
University of South Carolina Viral Vector Facility. Briefly, TRC2 Fh1 shRNA, clone-
TRCN0000246831 or SHC202 MISSION TRC2 pLKO.5-puro Non-Mammalian 
shRNA control plasmids (Sigma/Aldrich) were used to generate the lentiviral 
vectors. The specific vector plasmid packing, envelope and Rev plasmids were 
transfected into 293T cells. N1E-115 neuroblastoma cells obtained from Sigma 
were grown in 90% DMEM plus 10% fetal bovine serum (non-differentiation 
medium). At 80% confluence, the cells were washed with DPBS prior to the 
addition of the lentiviral vectors for transduction. Selection of transduced cells with 
puromycin (1.75 g/ml) started 2 days later and lasted for 1 week. At the end of this 
period, the remaining cells were expanded and differentiated into neurons in the 




5 days. The cells were harvested in RIPA buffer; protein extracts were subjected 
to immunoblotting 
Primary Neuron Isolation and Culture. Primary neurons from newborn mouse 
brain cortices were isolated and cultured using an adaptation of the method 
described by Brewer (141). Briefly, postnatal day 1 mice were sacrificed by 
decapitation, the brains were aseptically dissected and cortices were separated 
from the rest of the brain in ice-cold Hibernate A medium (Gibco/Thermo Fisher 
Scientific, Waltham, MA), containing 2% (v/v) B-27 supplement (Gibco/Thermo 
Fisher Scientific) and 0.5 mM glutamine (Invitrogen/Thermo Fisher Scientific, 
Waltham, MA). The tissue was minced in fragments of about 1 mm3 with a scalpel, 
and subjected to digestion with 2 mg/ml papain (Worthington Biochemical Corp., 
Lakewood, NJ) in the supplemented Hibernate A medium for 20 min at 30°C in a 
shaker incubator set at 100 rpm. After thorough trituration through a fire polished 
Pasteur pipette, the tissue was allowed to settle for 5 min and the supernatant was 
carefully layered on top of a discontinuous OptiPrep (Sigma-Aldrich) gradient 
prepared in Hibernate A medium; the layers contained 35, 25, 20 and 15% 
OptiPrep. The gradient was centrifuged at 800 g for 15 min at room temperature, 
and layers 1 (15% OptiPrep) 8 and 2 (20%) were discarded. Layer 3 (25%) was 
collected and added a five-fold volume of Neurobasal A medium (Gibco/Thermo 
Fisher Scientific), containing 0.5 mM glutamine and 2% B-27 supplement. After a 
centrifugation at 500 g for 5 min, cells were resuspended in Neurobasal A medium 
containing 0.5 mM glutamine, 2% B-27 supplement, and 5 ng/ml bFGF 




pretreated with 0.01% poly-L-lysine (Sigma-Aldrich) at a density of 200,000 
cells/well. Fifty percent of the media was replaced every third day, with the addition 
of 5 µM AraC from DIV 3 to inhibit glial proliferation. On DIV 8, cells were left 
untreated or treated with 5 mM NAC or NACA for 24 hours. Following, the cells 
were either subsequently treated with 100 µM DMF for an additional 5 hours, or 
left alone, resulting in 6 treatment groups (control, control + DMF, NAC, NAC + 
DMF, NACA or NACA + DMF).  
Glutathione Quantification. Cellular protein was washed 3 times with ice cold 
phosphate buffered saline (PBS) before being scraped and precipitated in 5% 
sulfosalicylic acid and sonicated, while tissue was placed into the acid and 
homogenized via glass mortar and pestle. Each solution was then allowed to sit 
on ice for 10 minutes and centrifuged at 14,000 rpm, +4°C for 10 minutes. The 
supernatant was removed and diluted 1:5 with assay buffer and then diluted 1:5 
with sample diluent buffer supplied by the commercially available kit (Arbor Assay 
Glutathione Fluorescent Detection Kit, Ann Arbor, MI). Glutathione standards were 
prepared via adding 50 µL Glutathione Standard into a tube of 450 µL sample 
diluent and vortexed. This was then serial diluted through seven other tubes using 
250 µL of the mixture. 50 µL of samples, standards and a glutathione control were 
pipetted in duplicate into a 96-well clear bottomed plate. 25 µL of the Thiostar 
reagent was added to each sample. Total glutathione levels were quantified 
according to the manufacturer’s instructions (fluorescent emission at 510 nm with 




before being read again on the plate reader. This allowed for calculations of total 
and oxidized glutathione concentrations. 
 The pellet remaining at the bottom of the centrifuged sample was 
resuspended in RIPA+ buffer and protein levels quantified via the Lowry method 
(140).    
Fumarate Extraction & Quantification. Fh KD and Scr differentiated N1E-115 
cells were washed three times with ice-cold PBS followed by the immediate 
addition of ice-cold chloroform/methanol (2:1) and scraping. After 10 min on ice, 
0.2 volumes of water were added, followed by centrifugation at 3,220 g for 20 min. 
The extraction was repeated, and the aqueous supernatants were dried. The 
protein interface for each sample was removed for protein quantification. After 
TMS derivatization of the extracts, samples were injected into an Agilent 7890A 
GC system, coupled to an Agilent 5975C electron ionization mass selective 
detector. Selected ion monitoring was performed for fumarate and the peak areas 
obtained were normalized to the added internal standard. Absolute quantitation 
was performed based on standard curves obtained from the normalized reference 
standards, and the final metabolite concentrations were normalized to the protein 
content of the cells. Note: Fumarate analysis was performed at DHMRI in 
Charlotte, NC. 
Determination of the Oxygen Consumption Rate (OCR). N1E-115 Scr and Fh 
KD cells were seeded on V7 cell culture microplates coated with 0.2% gelatin at a 




5 days as described above, and treated with 0, 10 or 50 µM DMF for the last 24 
hours (n=8/group). The Seahorse extracellular flux analyzer XF-24 (Agilent 
Technologies, INC., Santa Clara, CA), was used to measure the oxygen 
consumption rate (OCR), using XF Assay Medium supplemented with 25 mM 
glucose (142). After measurement of basal respiration, oligomycin (5 µg/mL), 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (0.5 µM), 
rotenone/antimycin A (3 µM/4 µM) were added sequentially to determine ATP 
production/proton leak, spare respiratory capacity and non-mitochondrial 
respiration. After completion of the assay, the medium was removed and the cells 
were immediately washed 3 times with cold PBS. The plate was stored at -70°C 
prior to the measurement of the total protein content to normalize individual 
measurements. 
Tissue Sulfenic Acid Stabilization. Olfactory bulbs and brainstems p21 (young) 
and p46 (old) mice were harvested and immediately placed into buffer containing 
250 mM Hepes and 1 mM DTPA, pH to 7.7 and add 20 mM NEM, 10 mM 
Dimedone, 1% Triton-X, 2 mM NaF, 2 mM SOV, 1/1000 protease inhibitor cocktail, 
and 200 U/mL catalase. These were then homogenized using mortar and pestle 
before being placed on a shaker for 30 minutes prior to centrifugation for 10 min 
at 14,000 rpm at 4°C. The supernatant was removed to perform the Lowry method 
(140) and subsequent western blotting.  
Immunoblotting. 20-40 µg cell lysate protein or 20-40 µg protein from mouse 
brain tissue was diluted to total volume with nano-pure deionized water and 




were centrifuged at 5000 rpm for 10 seconds and then loaded on 7.5%, 12% or 
18% gels and electrophoresed at 200 volts for 60 minutes. The protein was 
transferred to a PVDF membrane in transfer buffer (0.1% Tris Base, 20% 
methanol, 79.9% nano-pure deionized water) at 250 mA for 100 minutes or 40 mM 
overnight at 4°C. The membrane protein loading was visualized with Ponceau Red, 
followed by blocking in 5% bovine serum albumin (BSA) or 5% 134 non-fat milk for 
1 hour at room temperature, or overnight at 4°C according to the antibody 
manufacturer’s recommendations. Primary polyclonal antibody to actin (sc-1616) 
(1:5,000) was from Santa Cruz Biotechnology Inc. (Dallas, TX). Polyclonal 
antibodies to GFAP (3670) (1:30,000), DM1A Tubulin (3873) (1:15,000) and β3 
Tubulin (5666) (1:30,000) were from Cell Signaling (Danvers, MA). The anti-HNE 
(HNE11-S) (1:5,000) was from Alpha Diagnostic International Inc. (San Antonia, 
TX). Polyclonal antibody to glutathione (101-A) (1:2,000) was from Virogen 
(Watertown, MA). Polyclonal sulfenic acid was from EMD Millipore (ABS30) 
(1:15,000). The polyclonal anti-2SC antibody was prepared as described 
previously (Nagai et al. 2007) (1:6,000). Polyclonal antibody to IBA-1 (016-20001) 
(1:1,000) was purchased from Wako Pure Chemical Industries Ltd. (Richmond, 
VA). Chemiluminescent substrate (Thermo Pierce, Rockford, IL) was utilized 
followed by detection on photographic film (Denville Scientific, Metuchen, NJ). 
Immunoblots were stripped (62.5 mM Tris, pH 6.8, 2% SDS and 0.7% (v/v) beta 
mercaptoethanol) for 20 minutes at 67°C prior to re-probing with new primary 




band intensity by densitometry. All immunoblots were normalized to protein 
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Appendix A Seahorse Cell Mitochondrial Respiration Stress Test. A) 
Oligomycin, FCCP, and a combination of rotenone and antimycin A are serially 
injected into the cells. These measure ATP-linked respiration, maximal 
respiration, and non-mitochondrial respiration, respectively. Using these 
measurements, as well as their basal respiration, proton leak and spare 









Radio Immunoprecipitation Buffer  
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2mM EDTA, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% Triton-X. Dissolve in 200 mL with DI water and 
store at +4. On the day of use, add 2 mM sodium orthovanadate, 2 mM sodium 
fluoride and protease inhibitor cocktail at 1:1000 dilution. 
10x Wash Buffer 
200 mM Tris-HCl pH 7.4 in 1 mL DI water. 0.05% Tween-20 was added to 1x 
wash buffer. 
10x Transfer Buffer 
250 mM Tris-HCl and 1920 mM glycine dissolved in 1 mL DI water. 
1x Transfer Buffer 
700 mL DI water, 200 mL methanol and 100 mL 10x Transfer buffer. 
10x SDS Running Buffer 
250 mM Tris-HCl, 1920 mM glycine and 1% SDS was added to 1 mL water. 
Stripping Buffer 
Add 3.785 grams Tris-Base to ~400 mL nano-pure water pH 6.8. Dissolve 10 
grams SDS and bring the final volume to 500 mL with nano-pure water. Before 





4x Laemmli Loading Buffer 
Dissolve 0.969 grams Tris-Base in 10 mL nano-pure water and pH 6.8. Add 
2.468 g~8rams DTT, 3.2 grams SDS, 16 mL glycerol and ~8 milligrams 
bromophenol blue for color. Store at -20ºC. 
Coomassie Stain 
Stir 400 mL nano-pure water, 100 mL glacial acetic acid and 500 mL methanol 
for 10 mins. Add 2.5 grams Coomassie Brilliant Blue R-250 (*Do not use G-
250*) and stir fat least 2 hours at room temperature. Filter staining solution 
using a 0.45 µm Zap Cap and vacuum aspirator. 
Coomassie Destain 






Balance Beam Protocol 
Set up: 
1) Place beam (7mm) on an incline of 4º, with the end of the beam higher 
than the starting point. 
2) Add food and bedding (from the cage being used) to the ending platform. 
Habituation:  
 Transfer mice into testing space 30-60 minutes prior to training/testing to 
 allow for acclimation.  
 Note: NACA mice did not undergo habituation. 
Training: 
1) Set first mouse on the platform and place the black box over them, allow 
to sit for 20 seconds to acclimate. 
2) Take the mouse out of the box and place on beam approximately 2-3 





3) Repeat the training at 1/3 of the way down the beam, 1/2 and 2/3 before 
placing mouse at the starting point on the beam and having them 
walk/run into the box (allow mouse~15 sec inside box to recuperate). 
Note: Keep something under KO mice (hands, cage lid, etc) in case of 
fall 
4) Repeat training until the mouse is able to transverse the beam without 
assistance. 
Testing: 
1) Allow mouse 30 seconds in the box with bedding and food for 
acclimation. 
2) Place mouse at the starting point on the beam, beginning timing and 
counting of paw slips, ending when its nose reaches the black box. 
3) Permit the mouse time to recuperate in the box (WT: 15-20 sec, KO: 30-
40 sec) before starting the next trial. 
4) Repeat 4x per mouse, with the 3 best times used in statistics. 
5) Use alcohol to clean the balance beam in between mice. 
6) When switching to a mouse from a different cage, also switch the 
 bedding to maintain a familiar scent for the mice to run towards. 
Rotarod Protocol  
Set up: 
1) Set the removable platforms at an angle, they will click into place, in 





 Transfer mice into testing space 30-60 minutes prior to training/testing to 
 allow for acclimation.  
 Note: NACA mice did not undergo habituation. 
Training:  
1) Place one mouse in between each set of partitions, allow to sit for one 
minute, before removing them. 
2) Set the rotarod to a fixed speed at 4 rpm, place the mice back onto the 
machine and start the wheel, letting it rotate for one minute. 
3) Set the rotarod to accelerated mode, with the minimum at 4 rpm and 
max at 40 rpm, this will also be for 1 minute. The mice should always be 
placed on the wheel while it is stopped.  
Testing: 
1) Using the accelerating function, set the minimum at 4 rpm and the max 
at 40 rpm, constantly accelerating for 5 minutes.  
2) Place mice on wheel, making sure the platforms are up, and begin 
testing 
3) When a mouse falls from the wheel and hits the platform, the time from 
start to fall will be displayed on the screen. 
4) Repeat this process with the next cage. One run should be performed 




cages in this way should allow mice a resting period of ~20-30 minutes, 
dependent upon the number of cages 
5) Mice are to be tested four times each.  
6) In PLX study, each run was recorded and later analyzed for 
cartwheeling. This provided the amount of time the mice spent running 
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